eXoZymes Inc. achieves a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process using its exozyme-based platform.
The conversion level of over 99% from feedstock to product marks a significant milestone in the scalability of the exozymes platform.
The successful scale-up demonstrates the potential of cell-free biomanufacturing enhanced by AI-driven enzymes at eXoZymes.
Scalability Milestone
Achieving a 100-fold scale-up with over 99% conversion rate showcases the promising future of exozymes in biomanufacturing.
High Efficiency
The exceptionally high conversion efficiency of the scaled reaction confirms the robustness and reliability of the exozyme-driven process.
Future Research
Collaboration with Cayman Chemical for NCT isolation and data analysis promises further advancements in exozyme technology.
- The successful 100x scale-up marks a significant advancement in biomanufacturing capabilities.
- eXoZymes' achievement in converting feedstock to product with over 99% efficiency demonstrates the effectiveness of their cell-free biomanufacturing platform.
eXoZymes' breakthrough in scaling up NCT production with high conversion rates sets a new standard in biomanufacturing efficiency and sustainability, paving the way for innovative nutraceutical and medicinal developments.